S&P 500   3,452.92 (+0.51%)
DOW   28,385.04 (+0.62%)
QQQ   284.44 (+0.09%)
AAPL   115.68 (-1.02%)
MSFT   214.95 (+0.07%)
FB   278.08 (-0.23%)
GOOGL   1,606.78 (+1.31%)
AMZN   3,175.00 (-0.31%)
TSLA   429.12 (+1.53%)
NVDA   536.21 (-0.88%)
BABA   306.44 (-0.50%)
CGC   20.01 (+2.67%)
GE   7.72 (+5.46%)
MU   54.78 (+2.76%)
AMD   79.89 (+0.87%)
T   28.29 (+5.88%)
F   8.14 (+3.69%)
ACB   4.76 (-1.86%)
GILD   60.24 (+0.05%)
NFLX   484.03 (-1.03%)
BA   169.41 (+3.39%)
NIO   27.42 (-1.58%)
DIS   127.70 (+0.84%)
S&P 500   3,452.92 (+0.51%)
DOW   28,385.04 (+0.62%)
QQQ   284.44 (+0.09%)
AAPL   115.68 (-1.02%)
MSFT   214.95 (+0.07%)
FB   278.08 (-0.23%)
GOOGL   1,606.78 (+1.31%)
AMZN   3,175.00 (-0.31%)
TSLA   429.12 (+1.53%)
NVDA   536.21 (-0.88%)
BABA   306.44 (-0.50%)
CGC   20.01 (+2.67%)
GE   7.72 (+5.46%)
MU   54.78 (+2.76%)
AMD   79.89 (+0.87%)
T   28.29 (+5.88%)
F   8.14 (+3.69%)
ACB   4.76 (-1.86%)
GILD   60.24 (+0.05%)
NFLX   484.03 (-1.03%)
BA   169.41 (+3.39%)
NIO   27.42 (-1.58%)
DIS   127.70 (+0.84%)
S&P 500   3,452.92 (+0.51%)
DOW   28,385.04 (+0.62%)
QQQ   284.44 (+0.09%)
AAPL   115.68 (-1.02%)
MSFT   214.95 (+0.07%)
FB   278.08 (-0.23%)
GOOGL   1,606.78 (+1.31%)
AMZN   3,175.00 (-0.31%)
TSLA   429.12 (+1.53%)
NVDA   536.21 (-0.88%)
BABA   306.44 (-0.50%)
CGC   20.01 (+2.67%)
GE   7.72 (+5.46%)
MU   54.78 (+2.76%)
AMD   79.89 (+0.87%)
T   28.29 (+5.88%)
F   8.14 (+3.69%)
ACB   4.76 (-1.86%)
GILD   60.24 (+0.05%)
NFLX   484.03 (-1.03%)
BA   169.41 (+3.39%)
NIO   27.42 (-1.58%)
DIS   127.70 (+0.84%)
S&P 500   3,452.92 (+0.51%)
DOW   28,385.04 (+0.62%)
QQQ   284.44 (+0.09%)
AAPL   115.68 (-1.02%)
MSFT   214.95 (+0.07%)
FB   278.08 (-0.23%)
GOOGL   1,606.78 (+1.31%)
AMZN   3,175.00 (-0.31%)
TSLA   429.12 (+1.53%)
NVDA   536.21 (-0.88%)
BABA   306.44 (-0.50%)
CGC   20.01 (+2.67%)
GE   7.72 (+5.46%)
MU   54.78 (+2.76%)
AMD   79.89 (+0.87%)
T   28.29 (+5.88%)
F   8.14 (+3.69%)
ACB   4.76 (-1.86%)
GILD   60.24 (+0.05%)
NFLX   484.03 (-1.03%)
BA   169.41 (+3.39%)
NIO   27.42 (-1.58%)
DIS   127.70 (+0.84%)
Log in
NASDAQ:CBMG

Cellular Biomedicine Group Stock Forecast, Price & News

$18.40
0.00 (0.00 %)
(As of 10/22/2020 02:11 PM ET)
Add
Compare
Today's Range
$18.33
Now: $18.40
$18.41
50-Day Range
$18.14
MA: $18.41
$18.70
52-Week Range
$11.48
Now: $18.40
$19.50
Volume495 shs
Average Volume42,214 shs
Market Capitalization$357.51 million
P/E RatioN/A
Dividend YieldN/A
Beta1.57
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.
Read More
Cellular Biomedicine Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.66 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBMG
CUSIPN/A
Phone347-905-5663
Employees217

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$340,000.00
Book Value$2.89 per share

Profitability

Net Income$-49,980,000.00

Miscellaneous

Market Cap$357.51 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$18.40
0.00 (0.00 %)
(As of 10/22/2020 02:11 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBMG News and Ratings via Email

Sign-up to receive the latest news and ratings for CBMG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions

How has Cellular Biomedicine Group's stock been impacted by COVID-19 (Coronavirus)?

Cellular Biomedicine Group's stock was trading at $14.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CBMG stock has increased by 27.0% and is now trading at $18.40.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Cellular Biomedicine Group?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Cellular Biomedicine Group
.

When is Cellular Biomedicine Group's next earnings date?

Cellular Biomedicine Group is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Cellular Biomedicine Group
.

How were Cellular Biomedicine Group's earnings last quarter?

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) released its earnings results on Wednesday, August, 12th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.57) by $0.13.
View Cellular Biomedicine Group's earnings history
.

What price target have analysts set for CBMG?

2 Wall Street analysts have issued 1-year target prices for Cellular Biomedicine Group's shares. Their forecasts range from $19.00 to $19.00. On average, they anticipate Cellular Biomedicine Group's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 3.3% from the stock's current price.
View analysts' price targets for Cellular Biomedicine Group
.

Are investors shorting Cellular Biomedicine Group?

Cellular Biomedicine Group saw a decrease in short interest during the month of September. As of September 30th, there was short interest totaling 378,300 shares, a decrease of 14.3% from the September 15th total of 441,400 shares. Based on an average daily volume of 135,300 shares, the days-to-cover ratio is presently 2.8 days. Approximately 3.3% of the company's stock are sold short.
View Cellular Biomedicine Group's Short Interest
.

Who are some of Cellular Biomedicine Group's key competitors?

What other stocks do shareholders of Cellular Biomedicine Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellular Biomedicine Group investors own include Crispr Therapeutics (CRSP), Aduro BioTech (ADRO), Amarin (AMRN), Anavex Life Sciences (AVXL), Adaptimmune Therapeutics (ADAP), Exelixis (EXEL), Fate Therapeutics (FATE), ImmunoGen (IMGN), AT&T (T) and Iovance Biotherapeutics (IOVA).

Who are Cellular Biomedicine Group's key executives?

Cellular Biomedicine Group's management team includes the following people:
  • Mr. Bizuo Liu, CEO, CFO & Exec. Director (Age 55, Pay $541.33k)
  • Dr. Yihong Yao, Chief Scientific Officer (Age 52, Pay $364.98k)
  • Mr. Andrew K. Chan, Chief Legal Officer, Sr. VP of Corp. Devel. & Sec. (Age 62, Pay $475.08k)
  • Mr. Derrick C. Li, Head of Strategy & Investor Relations
  • Ms. Sarah Kelly, Director of Corp. Communications
  • Dr. Li Zhang, Chief Production Officer
  • Prof. Zhong Chen Kou, Chief Scientist of Immunology
  • Dr. Xia Meng Ph.D., BS, Head of Early Diagnosis & Intervention
  • Mr. Michael Humphries, Head of Devel. & Strategy

What is Cellular Biomedicine Group's stock symbol?

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

Who are Cellular Biomedicine Group's major shareholders?

Cellular Biomedicine Group's stock is owned by many different institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (1.21%) and Nisa Investment Advisors LLC (0.02%).
View institutional ownership trends for Cellular Biomedicine Group
.

Which major investors are buying Cellular Biomedicine Group stock?

CBMG stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., and Nisa Investment Advisors LLC.
View insider buying and selling activity for Cellular Biomedicine Group
.

How do I buy shares of Cellular Biomedicine Group?

Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cellular Biomedicine Group's stock price today?

One share of CBMG stock can currently be purchased for approximately $18.40.

How big of a company is Cellular Biomedicine Group?

Cellular Biomedicine Group has a market capitalization of $357.51 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-49,980,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Cellular Biomedicine Group employs 217 workers across the globe.

What is Cellular Biomedicine Group's official website?

The official website for Cellular Biomedicine Group is www.cellbiomedgroup.com.

How can I contact Cellular Biomedicine Group?

Cellular Biomedicine Group's mailing address is 1345 AVENUE OF AMERICAS 15TH FLOOR, NEW YORK NY, 10105. The biotechnology company can be reached via phone at 347-905-5663 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.